Susan Bal

University of Alabama at Birmingham — United States

Medicine · Health Sciences

18h-index1.5kcitations171works2.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(108), Protein Degradation and Inhibitors(56), CAR-T cell therapy research(24), Peptidase Inhibition and Analysis(23), Chronic Lymphocytic Leukemia Research(14)

Publications171 total

Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials
UNC Libraries·2025Open Access
Identifying candidates for outpatient administration of ciltacabtagene autoleucel (Cilta-cel) in relapsed-refractory multiple myeloma (RRMM)
Blood·2025
Real world efficacy and safety of elranatamab, a BCMA bispecific antibody for patients with relapsed and refractory multiple myeloma: An international myeloma working group immunotherapy database analysis
Blood·2025
Trial in progress: QUINTESSENTIAL-2—a phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide
Blood·2025
Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality
Blood·2025
Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
Blood·2025Open Access
Redefining function high-risk (FHR) multiple myeloma (MM) in the context of upfront quadruplet (QUAD) therapy and autologous stem cell transplantation (ASCT)
Blood·2025Open Access
Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium
Blood·2025· 1 citedOpen Access
Assessment of pharmacodynamic efficacy biomarkers from A phase 1, first-in-human study of arlocabtagene autoleucel (arlo-cel) in relapsed and refractory multiple myeloma (RRMM)
Blood·2025Open Access
An open-label multicenter Phase 1/2 trial of venetoclax-dexamethasone in Relapsed/Refractory t(11;14)-positive systemic AL amyloidosis
Blood·2025Open Access
Distinct trajectory and prognosis of measurable residual disease (MRD) in t(11;14) multiple myeloma (MM) treated with upfront quadruplet (QUAD) therapy and autologous stem cell transplantation (ASCT)
Blood·2025Open Access
Talquetamab for relapsed/refractory multiple myeloma : Real-world outcomes from the US multiple myeloma immunotherapy consortium
Blood·2025
Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis
Blood·2025Open Access
Reversing the sequence: Efficacy of BCMA‐directed therapy following progression on <scp>GPRC5D</scp> ‐directed therapies in relapsed multiple myeloma
British Journal of Haematology·2025
Prevalence and Associated Factors of Overweight and Obesity Among Younger Adult Diabetes Mellitus Patient—A Cross Sectional Study
Lecture notes in networks and systems·2025
Trial in Progress: QUINTESSENTIAL-2—A Phase 3 Study of Arlocabtagene Autoleucel Vs Standard of Care in Adult Patients With Relapsed and Refractory Multiple Myeloma (RRMM) Refractory to Lenalidomide
Clinical Lymphoma Myeloma & Leukemia·2025
Arlocabtagene Autoleucel, a GPRC5D-Targeted CAR T-Cell Therapy for Patients With Relapsed/Refractory Multiple Myeloma: Updated Phase 1 Safety and Efficacy Results in Patients With 1–3 Prior Regimens
Clinical Lymphoma Myeloma & Leukemia·2025
Long-term Follow-Up of a Phase 1 Study of Arlocabtagene Autoleucel (arlo-cel; BMS-986393) in Patients With Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM)
Clinical Lymphoma Myeloma & Leukemia·2025
Trial in Progress: QUINTESSENTIAL—A Phase 2 Study of Arlocabtagene Autoleucel (arlo-cel) in Triple- and Quad-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma (RRMM)
Clinical Lymphoma Myeloma & Leukemia·2025
MM-1157: Trial in Progress: Quintessential—A Phase 2 Study of Arlocabtagene Autoleucel in Triple- and Quad-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025
page 1 of 9Next →

Frequent Co-authors

Luciano J. Costa(38), Kelly Godby(22), Smith Giri(22), Natalie S. Callander(14), Saurabh Chhabra(12), Bhagirathbhai Dholaria(9), Rebecca Silbermann(9), Robert F. Cornell(9), Eva Medvedova(8), Timothy M. Schmidt(8), Anita D’Souza(8), Parameswaran Hari(8), Gayathri Ravi(7), Binod Dhakal(6), Saad Z. Usmani(6), Jesús G. Berdeja(6), Larry D. Anderson(6), Pamela Hardwick(5), Shaji Kumar(5), Aric C. Hall(4)